238 related articles for article (PubMed ID: 20378421)
1. Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
Moore JE; Maeda Y; Goldsmith CE; Rendall JC; Elborn JS
J Cyst Fibros; 2010 May; 9(3):237-8. PubMed ID: 20378421
[No Abstract] [Full Text] [Related]
2. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
[TBL] [Abstract][Full Text] [Related]
3. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
4. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
Lapointe JR; Bourget C; Mainville S; Lafleur L; Lagacé J; Montplaisir S
J Chemother; 1989 Jul; 1(4 Suppl):184-6. PubMed ID: 16312360
[No Abstract] [Full Text] [Related]
5. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
[TBL] [Abstract][Full Text] [Related]
6. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
Woodward TC; Brown R; Sacco P; Zhang J
J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.
Petrova G; Strateva T; Miteva D; Lazova S; Perenovska P
J Infect Dev Ctries; 2016 Nov; 10(11):1265-1267. PubMed ID: 27886041
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.
Rao P; McCaughan J; McCalmont M; Goldsmith CE; Hall V; Millar BC; McCann MA; Downey DG; Rendall JC; Elborn JS; Moore JE
J Cyst Fibros; 2012 Jul; 11(4):349-52. PubMed ID: 22325689
[No Abstract] [Full Text] [Related]
9. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
11. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
Chuchalin A; Amelina E; Bianco F
Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
[TBL] [Abstract][Full Text] [Related]
13. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
Bosso JA; Mauldin PD; Steed LL
Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
[TBL] [Abstract][Full Text] [Related]
14. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
15. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
16. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL
J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
[TBL] [Abstract][Full Text] [Related]
17. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.
Berlana D; Llop JM; Manresa F; Jódar R
Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493
[TBL] [Abstract][Full Text] [Related]
18. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Vandenbussche HL; Klepser ME
Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
[No Abstract] [Full Text] [Related]
19. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
[TBL] [Abstract][Full Text] [Related]
20. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
Pierart F
Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
